病毒学报

参考文献

[1]Nina J.Ebolavirosis:a 2014review for clinicians[J].Acta Med Port,2014,27(5):625-633.

[2]Paessler S,Walker D H.Pathogenesis of the viral hemorrhagic fevers[J].Annu Rev Pathol,2013,8:411-440.

[3]Cox N J,McCormick J B,Johnson K M,Kiley M P.Evidence for two subtypes of Ebola virus bas-ed on oligonucleotide mapping of RNA[J].J Infect Dis,1983,147:272-275.

[4]World Health Organization.Ebola haemorrhagic fever in Zaire,1976[R].Word Health Organ,1978,56:271-293.

[5]Wikipedia Ebolavirus[EB/OL].http://it.wikipedia.org/wiki/Ebolavirus.2014

[6]Feldmann H,Geisbert T W.Ebola haemorrhagic fever[J].Lancet,2011,377:849-862.

[7]MacNeil A,Rollin P E.Ebola and marburg hemorrhagic fevers:neglected tropical diseas-es?[J/OL].PLoS Negl Trop Dis,2012,6(6):1546-1551.

[8]CDC,2014Ebola outbreak in West Africa[EB/OL].http://www.cdc.gov/vhf/ebola/outbreaks/guinea/index.html.2014

[9]Geisbert T W,Bailey M,Hensley,Asiedu C,Geisbert J,Stanley D,Honko A,Johnson J,Mulangu S,Pau MG,Custers J,Vellinga J,Hendriks J,Jahrling P,Roederer M,Goudsmit J,Koup R,Sullivan NJ.Recombinant adenovirus serotype 26(Ad26)and Ad35vaccine vectors bypass immunity to Ad5and protect nonhuman primates against ebolavirus challenge[J].J Virol,2011,85(9):4222-4233.

[10]Williams K J,Qiu X,Fernando L.VSVΔG/EBOV GPinduced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted ebola virus infection[J].Viral Immunol,2015,28(1):51-61.

[11]Chad E.Mire,Joan B.Geisbert,Andrea Marzi,Krystle N.Agans,Heinz Feldmann,Thomas W.Geisbert.Vesicular stomatitis virus-based vaccines protect nonhuman primates against bundibugyo ebolavirus[J/OL].PLoS Negl Trop Dis,2013,7(12):e2600.

[12]杨臻峥,邢爱敏,康银花等.抗埃博拉病毒药物研究近期动态[J].药学进展,2014,9:707-711.

[13]Johnson and Johnson Inc.JNJ announce start of phase 1clinical trail of ebola vaccine regimen[EB/OL].http://www.jnj.com/news/.2015-1-6.

[14]Shedlock D J,Avile J,Talbott K T,Wong G,Wu S J,Villarreal D O,Myles D J,Croyle M A,Yan J,Kobinger G P,Weiner D B.Induction of broad cytotoxic T cells by protective DNA vaccination against marburg and ebola[J].Mol Ther,2013,21(7):1432-1444.

[15]Vanderzanden L,Bray M,Fuller D,Roberts T,Custer D,Spik K,Jahrling P,Huggins J,Schmaljohn A,Schmaljohn C.DNA vaccines expressing either the GP or NP genes of ebola virus protect mice from lethal challenge[J].Virology,1998,246(1):134-144.

[16]孟现民,董平,卢洪洲.埃博拉病毒病的治疗及新药研究进展[J].上海医药,2014,35(21):1-5.

[17]Warren T K,Wells J,Panchal R G,et al.Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430[J].Nature,2014,508(7496):402-415.

[18]Julander J G,Bantia S,Taubenheim,Stuthman K S,Garza N L,Van Tongeren S A,Dong L,Retterer C J,Eaton B P,Pegoraro G,Honnold S,Bantia S,Kotian P,Chen X,Taubenheim B R,Welch L S,Minning D M,Babu Y S,Sheridan W P,Bavari S.BCX4430,a novel nucleoside analog effectively treats yellow fever in a Hamster model[J].Antimicrob Agents Ch,2014,58(11):6607-6614.

[19]Paul Rodgers.Biowar lab develops cure for ebola[EB/OL].http://www.forbes.com/sites/paulrodgers/.2014-8-4

[20]Florescu D F,Keck M A.Development of CMX001(Brincidofovir)for the treatment of seri-ous diseases or conditions caused by dsDNA viruses[J].Expert Rev Anti Infect Ther,2014,12(10):1171-1178.

[21]Olson V A,Smith S K,Foster S,Li Y,Lanier E R,Gates I,Trost L C,Damon IK.In vitro efficacy of brincidofovir against variola virus[J].Antimicrob Agents Ch,2014,58(9):5570-5581.

[22]Bronze M S,Greenfield R A.Therapeutic options foe disease due potential viral agents of bio-terrorism[J].Curr Opin Investig Drug,2003,4(2):172-178.

[23]Oestereich L,Ludtke A,Wurr S,Rieger T,Mun~oz-Fontela C,Günther S.Successful treatment of advanced Ebola virus infection with T-705(favipiravir)in a small animal model[J].Antiviral Res,2014,105:17-21.

[24]Geisbert T W,Lee A C,Robbins M,Geisbert J B,Honko A N,Sood V,Johnson J C,de Jong S,Tavakoli I,Judge A,Hensley L E.Maclachlan I.Postexposure protection of non-human primates against a lethal ebola virus challengewith RNA interference:aproof-of-concept study[J].Lancet,2010,375(9279):1896-1905.

[25]Gowen B B,Smee D F,Wong M H,Hall J O,Jung K H,Bailey K W,Stevens J R,Furuta Y,Morrey J D.Treatment of late stage disease in a model of arena-viral hemorrhagic fever:T-705efficacy and reduced toxicity suggests an alternative to riba-virin[J/OL].PLoS One,2008,3:e3725.

[26]Pettitt J,Zeitlin L,Kim D H,Working C,Johnson J C,Bohorov O,Bratcher B,Hiatt E,Hume S D,Johnson A K,Morton J,Pauly M H,Whaley K J,Ingram M F,Zovanyi A,Heinrich M,Piper A,Zelko J,OlingerG G.Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail[J].Sci Transl Med,2013,5,199ra113.

[27]Igor Kolotilin,Ed Topp,Eric Cox,Devriendt B,Conrad U,Joensuu J,Stger E,Warzecha H,McAllister T,Potter A,McLean M D,Hall J C,Menassa R.Plant-based solutions for veterinary immunothera-peutics and prophylactics[J].Vet Res,2014,45(1):375-383.

[28]Geisbert T W.Medical research:Ebola therapy protects severely ill monkeys[J].Nature,2014,514(7520):41-53.

[29]Qiu X,Wong G,Audet J,Bello A,Fernando L,Alimonti JB,Fausther-Bovendo H,Wei H,Aviles J,Hiatt E,Johnson A,Morton J,Swope K,Bohorov O,Bohorova N,Goodman C,Kim D,Pauly M H,Velasco J,Pettitt J,Olinger G G,Whaley K,Xu B,Strong J E,Zeitlin L,Kobinger G P.Reversion of advanced ebola virus disease in nonhuman primates with Zmapp[J].Nature,2014,514(7520):47-53.